- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT02615847
Clinical Trial to Study the Safety and Tolerability of Memantin Mepha® in Sickle Cell Disease Patients (MemSID)
A Phase II, Open Label, Single Center Trial to Study the Safety and Tolerability of Memantin Mepha® as Supportive Long Term Treatment in Symptomatic Sickle Cell Disease
Symptomatic sickle cell disease is worldwide the most frequent cause for hereditary hemolytic anemia with recurrent pain crisis. Hemolysis, vaso- occlusive and pain crises are hallmarks of this disease and are causative for an important socio-economic burden worldwide, especially in Africa.
Aside from allogenic stem cell transplantation, which is rarely available and very expensive, at present there is no curative treatment for patients with sickle cell disease (SCD). The current standard of care includes treatment with hydroxycarbamide and symptomatic care such as transfusions, antibiotic/analgesic treatment.
This study has the aim to study the safety and tolerability of Memantin in patients with sickle cell disease.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
During the study participants will be asked if medical occurrences (AEs) happened and laboratory analysis (haematology, coagulation, chemistry) and urine samples will be taken. In addition at each visit a physical examination and measurement of vital signs will be performed.
In addition the number of hospital days and emergency consultations, the impact on working ability (the number of days with inability to work, changes in iv%), the amount and type of analgesic medication, the amount of RBC transfusions, the number of days that antibiotics prescribed and haematology (at local and external laboratory) and chemistry laboratory parameters will be assessed. For the impact on work and social life a questionnaire of quality of life will be filled out monthly by the patient.
At screening and at the end of the study SCD specific assessments will be performed, which include cardiologic examination (ECG, ECHO), abdominal sonography, ophthalmological examination, lung function testing and neuroangiologic examination.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
-
Zürich, Zwitserland, 8091
- University Hospital Zurich
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
Documented symptomatic sickle cell disease (HbSS or HbS/beta thalassemia)
- Age 18 years or older
- Able and willing to provide written informed consent and to comply with the study protocol procedures
- Willing to use two effective methods of contraception during study treatment until 6 months after stop of study treatment. Effective contraception methods are considered oral, injectable, implantative contraceptives or intrauterine contraceptive devices combined with the use of condom.
Exclusion Criteria:
History of transfusion during last three months before Screening
- Patients with active bacterial, viral or fungal infection requiring systemic treatment
- Patients with known infection with human immunodeficiency virus (HIV) of human T cell leukaemia virus 1 (HTLV-1)
- Inadequate renal function: creatinine clearance < 30ml/min
- Inadequate liver function: NCICTC Grade 3 liver function tests (AST, ALT > 5x upper limit of normal (ULN))
- History of malignancy
- Women who are pregnant or breast feeding
- Previous known mental disorder or known family history of psychiatric diseases
- Known epileptic disease
- The receipt of any investigational product within 30 days prior to this trial
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: Memantin arm
Memantinhydrochlorid, administered once per day during 12 month.
Dosage is from 0-20 mg.
|
Memantin Mepha® Lactabs (memantinehydrochlorid) will be provided as 5 mg, 10 mg, 15 mg and 20 mg tablets, packed in blister. The study drug will be taken once a day per os, during 12 month.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
Number of participants with treatment related adverse events as assessed by CTCAE version 4.0
Tijdsspanne: 14 month
|
14 month
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Haemoglobin in g/l
Tijdsspanne: 38 month
|
2 years before screening until end of study.
|
38 month
|
Erythrocytes in T/l
Tijdsspanne: 38 month
|
2 years before screening until end of study.
|
38 month
|
Reticulocytes in G/l
Tijdsspanne: 38 month
|
2 years before screening until end of study.
|
38 month
|
Haptoglobin in g/l
Tijdsspanne: 38 month
|
2 years before screening until end of study.
|
38 month
|
Billirubin in micmol/l
Tijdsspanne: 38 month
|
2 years before screening until end of study.
|
38 month
|
LDH (Lactat dehydrogenase) in U/l
Tijdsspanne: 38 month
|
2 years before screening until end of study.
|
38 month
|
Ferritin in micg/l
Tijdsspanne: 38 month
|
2 years before screening until end of study.
|
38 month
|
Transferrin saturation in %
Tijdsspanne: 38 month
|
2 years before screening until end of study.
|
38 month
|
Number of days in hospital
Tijdsspanne: 38 month
|
2 years before screening until end of study.
|
38 month
|
Number of days with inability to work
Tijdsspanne: 38 month
|
2 years before screening until end of study.
|
38 month
|
Number of transfusions
Tijdsspanne: 38 month
|
2 years before screening until end of study.
|
38 month
|
Number of days taken antibiotics
Tijdsspanne: 38 month
|
2 years before screening until end of study.
|
38 month
|
Amount of pain medication in mg or ml
Tijdsspanne: 38 month
|
2 years before screening until end of study.
|
38 month
|
Pain scale
Tijdsspanne: 38 month
|
Scores range from 0 (no pain) to 10 (worst possible pain).
|
38 month
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie stoel: Jeroen Goede, MD, UniversitätsSpital Zürich
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- HbSS-MemSID
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Sikkelcelziekte
-
Peking University People's HospitalOnbekendNatural Killer Cell-gemedieerde immuniteitChina
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI); NovartisActief, niet wervendRefractaire Hurthle Cell-schildklierkankerVerenigde Staten
-
Hadassah Medical OrganizationOnbekendNatural Killer Cell-deficiëntie, familiaal geïsoleerdIsraël
-
Assistance Publique - Hôpitaux de ParisNog niet aan het werven
-
Bing HanVoltooidPure Red Cell Aplasia, verworvenChina
-
Peking University First HospitalWervingNiercelcarcinoom, Clear Cell, SomatischChina
-
National Institute of Diabetes and Digestive and...WervingSchildklierkanker | Papillaire schildklierkanker | Hurthle Cell-schildklierkanker | Tall Cell Variant Schildklierkanker | Folliculaire schildklierkankerVerenigde Staten
-
ExelixisVoltooidNiercelcarcinoom | Papillaire schildklierkanker | Folliculaire schildklierkanker | Huerthle Cell-schildklierkankerVerenigde Staten
-
Jeadran N. Malagón-RojasNog niet aan het wervenStress, psychisch | Ongerustheid | Blootstelling aan het milieu | Cortisol-overschot | Epigenetische stoornis | Natural Killer Cell Cytokine-productieColombia
-
National Institute of Diabetes and Digestive and...VoltooidPapillaire schildklierkanker | Hurthle Cell-schildklierkanker | Tall Cell Variant Schildklierkanker | Folliculaire schildklierkanker | Kwaadaardige Struma OvariiVerenigde Staten